AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Peroxiredoxin-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P32119

UPID:

PRDX2_HUMAN

Alternative names:

Natural killer cell-enhancing factor B; PRP; Thiol-specific antioxidant protein; Thioredoxin peroxidase 1; Thioredoxin-dependent peroxide reductase 1; Thioredoxin-dependent peroxiredoxin 2

Alternative UPACC:

P32119; A8K0C0; P31945; P32118; P35701; Q6FHG4; Q92763; Q9UC23

Background:

Peroxiredoxin-2, also known as Thiol-specific antioxidant protein, plays a crucial role in cellular defense mechanisms. It catalyzes the reduction of hydrogen peroxide and organic hydroperoxides, thereby protecting cells from oxidative stress. This protein is involved in various signaling cascades, including those of growth factors and tumor necrosis factor-alpha, by regulating intracellular H(2)O(2) levels.

Therapeutic significance:

Understanding the role of Peroxiredoxin-2 could open doors to potential therapeutic strategies. Its ability to detoxify peroxides and act as a sensor for hydrogen peroxide-mediated events positions it as a key player in the prevention of oxidative stress-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.